Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FULC 
Fulcrum Therapeutics Inc (FULC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: FULC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.19
1 Year Target Price $12.19
| 2 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.79% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 498.72M USD | Price to earnings Ratio - | 1Y Target Price 12.19 |
Price to earnings Ratio - | 1Y Target Price 12.19 | ||
Volume (30-day avg) 7 | Beta 2.93 | 52 Weeks Range 2.31 - 9.89 | Updated Date 10/24/2025 |
52 Weeks Range 2.31 - 9.89 | Updated Date 10/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.77% | Return on Equity (TTM) -30% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 307871001 | Price to Sales(TTM) 5.12 |
Enterprise Value 307871001 | Price to Sales(TTM) 5.12 | ||
Enterprise Value to Revenue 117.4 | Enterprise Value to EBITDA -3.09 | Shares Outstanding 54091588 | Shares Floating 23764057 |
Shares Outstanding 54091588 | Shares Floating 23764057 | ||
Percent Insiders 1.53 | Percent Institutions 101.42 |
Upturn AI SWOT
Fulcrum Therapeutics Inc
Company Overview
History and Background
Fulcrum Therapeutics Inc. was founded in 2016 with a focus on developing therapies for genetically defined rare diseases by modulating gene expression. The company's approach centers around targeting disease-causing genes to restore proper protein levels.
Core Business Areas
- Rare Disease Therapies Development: Fulcrum focuses on discovering and developing small molecule therapies that target disease-causing genes in rare genetic disorders. They primarily focus on disorders where gene expression is dysregulated.
Leadership and Structure
Fulcrum Therapeutics Inc. has a leadership team consisting of experienced executives in drug development and biotechnology. The organizational structure is centered around research and development, clinical operations, and commercial planning.
Top Products and Market Share
Key Offerings
- Losmapimod: Losmapimod is Fulcrum's lead product candidate being developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD). It is currently in clinical trials. There is no current market share data as it is not yet approved for use. Competitors include Acceleron Pharma (acquired by Merck) which was developing sotatercept.
Market Dynamics
Industry Overview
The rare disease therapeutics market is characterized by high unmet medical needs, regulatory incentives, and increasing investment in research and development. It is a growing market.
Positioning
Fulcrum Therapeutics Inc. is positioned as an innovator in gene expression modulation for rare genetic disorders. Their focus on FSHD with Losmapimod aims to address a significant unmet need.
Total Addressable Market (TAM)
The total addressable market for FSHD therapies is estimated to be in the hundreds of millions of dollars annually. Fulcrum is positioned to capture a significant portion of this market if Losmapimod is approved.
Upturn SWOT Analysis
Strengths
- Novel gene expression modulation platform
- Experienced leadership team
- Lead product candidate in clinical development for FSHD
- Strong intellectual property position
Weaknesses
- Reliance on a single lead product candidate
- High cash burn rate
- Clinical trial risk and regulatory approval uncertainties
- Limited commercialization experience
Opportunities
- Expansion of pipeline with new product candidates
- Potential for strategic partnerships and collaborations
- Favorable regulatory pathways for rare disease therapies
- Market growth in rare disease therapeutics
Threats
- Competition from other companies developing FSHD therapies
- Clinical trial failures
- Regulatory setbacks
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- MRK
- Private Companies and Research Institutions
Competitive Landscape
Fulcrum Therapeutics Inc. competes with larger pharmaceutical companies and research institutions in the rare disease space. They focus on differentiation through their gene expression modulation platform. The percentage market share is speculative as their products are not commercially viable yet.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth data not available in the context window. Refer to public filings for accurate data.
Future Projections: Future projections are dependent on the success of Losmapimod and pipeline development. Analyst estimates vary.
Recent Initiatives: Recent initiatives focus on advancing clinical trials for Losmapimod and expanding the pipeline.
Summary
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for genetically defined rare diseases. Their lead product, Losmapimod, is currently in clinical trials for FSHD, which poses risk and opportunity. They need to look out for clinical trial setbacks. If Losmapimod is successful, Fulcrum could experience significant growth. The future success relies heavily on clinical data, regulatory approvals, and ability to capture the market in FSHD if approved.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share percentages are estimated based on available information and should be regarded as an approximation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fulcrum Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2019-07-18 | CEO, President & Director Mr. Alexander C. Sapir | ||
Sector Healthcare | Industry Biotechnology | Full time employees 45 | Website https://www.fulcrumtx.com |
Full time employees 45 | Website https://www.fulcrumtx.com | ||
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.